Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma

References

• Zhang Y, Fang L, Zang Y, et al. CIP2A promotes proliferation, invasion and chemoresistance to cisplatin in renal cell carcinoma. J Cancer. 2018;9(21):4029.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang Y, Luo M, et al. Long noncoding RNA small nucleolar RNA host gene 1 (SNHG1) promotes renal cell carcinoma progression and metastasis by negatively regulating miR-137. Med Sci Monit. 2018;24:3824.
   PubMed Web of Science ®Google Scholar
• Yuan L, Zeng G, Chen L, et al. Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis. Int J Biol Sci. 2018;14(3):266. .
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang ZJ, Jian WG, et al. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway. Mol Cancer. 2019;18(1):15. .
   PubMedGoogle Scholar
• Rini BI, Hutson TE, Figlin RA, et al. Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clin Genitourin Cancer. 2018;16(4):298–304. .
   PubMed Web of Science ®Google Scholar
• Guo J, Jin J, Oya M, et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018;11(1):69. .
   PubMedGoogle Scholar
• Wang X, Sun W, Shen W, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol. 2016;64(6):1283–1294. .
   PubMed Web of Science ®Google Scholar
• Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 2014;114(9):1377–1388. .
   PubMed Web of Science ®Google Scholar
• Guo X, Yang Z, Zhi Q, et al. Long noncoding RNA OR3A4 promotes metastasis and tumorigenicity in gastric cancer. Oncotarget. 2016;7(21):30276–30294. .
   PubMedGoogle Scholar
• Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–1307.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA-lncRNA interactions. Methods Mol Biol. 2016;1402:271–286.
   Google Scholar
• Engreitz JM, Haines JE, Perez EM, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539(7629):452. .
   PubMed Web of Science ®Google Scholar
• Liu L, Pang X, Shang W, et al. Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway. Cell Cycle. 2018;18(3):257–263.
   Web of Science ®Google Scholar
• Gu P, Chen X, Xie R, et al. lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 2017;25(8):1959–1973. .
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen Y, et al. LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204. Am J Cancer Res. 2016;6(5):1099.
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Shahryari V, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322. .
   PubMed Web of Science ®Google Scholar
• Yiren H, Yingcong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16(1):174. .
   PubMed Web of Science ®Google Scholar
• Xue D, Lu H, Xu HY, et al. Long noncoding RNA MALAT 1 enhances the docetaxel resistance of prostate cancer cells via miR‐145‐5p‐mediated regulation of AKAP 12. J Cell Mol Med. 2018;22(6):3223–3237.
   PubMed Web of Science ®Google Scholar
• Fang Z, Zhao J, Xie W, et al. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppressing miR-184 expression. Cancer Med. 2017;6(12):2897–2908.
   PubMed Web of Science ®Google Scholar
• Cao L, Chen J, Ou B, et al. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother. 2017;93:570–579.
   PubMed Web of Science ®Google Scholar
• Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non‐small cell lung cancer development via modulating miR‐124/STAT3 axis. J Cell Physiol. 2018;233(9):6679–6688.
   PubMed Web of Science ®Google Scholar
• Chen S, Ma P, Zhao Y, et al. Biological function and mechanism of MALAT-1 in renal cell carcinoma proliferation and apoptosis: role of the MALAT-1–Livin protein interaction. J Physiol Sci. 2017;67(5):577–585. .
   PubMed Web of Science ®Google Scholar
• Zhang HM, Yang FQ, Chen SJ, et al. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumor Biol. 2015;36(4):2947–2955.
   PubMedGoogle Scholar
• Kulkarni P, Dasgupta P, Majid S, et al. miR-182-5p suppresses progression of renal cancer through cell cycle arrest by targeting lncRNA MALAT-1. Cancer Res. 2018. DOI:https://doi.org/10.1158/1538-7445.
   Google Scholar
• Li P, Zhang X, Wang H, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–751. .
   PubMed Web of Science ®Google Scholar
• Xie S, Qin C, Jin L, et al. Long noncoding RNA SNHG14 promotes breast cancer cell proliferation and invasion via sponging miR-193a-3p. Eur Rev Med Pharmacol Sci. 2019;23(6):2461–2468. .
   PubMed Web of Science ®Google Scholar
• Ji N, Wang Y, Bao G, et al. LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ. Pathol Res Pract. 2019;215(4):668–675.
   PubMed Web of Science ®Google Scholar
• Wang N, Feng Y, Xu J, et al. miR-362-3p regulates cell proliferation, migration and invasion of trophoblastic cells under hypoxia through targeting Pax3. Biomed Pharmacothe. 2018;99:462.
   PubMed Web of Science ®Google Scholar
• Li M, Liu Q, Lei J, et al. MiR-362-3p inhibits the proliferation and migration of vascular smooth muscle cells in atherosclerosis by targeting ADAMTS1. Biochem Biophys Res Commun. 2017;493(1):270–276.
   PubMed Web of Science ®Google Scholar
• Zou X, Zhong J, Li J, et al. miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells. Mol Med Rep. 2016;13(1):994–1002. .
   PubMed Web of Science ®Google Scholar
• Liu Z-S, Cai H, Xue W, et al. G3BP1 promotes DNA binding and activation of cGAS. Nat Immunol. 2019;20(1):18. .
   PubMed Web of Science ®Google Scholar
• Dou N, Chen J, Yu S, et al. G3BP1 contributes to tumor metastasis via upregulation of Slug expression in hepatocellular carcinoma. Am J Cancer Res. 2016;6(5):2641.
   PubMedGoogle Scholar
• Wang Y, Fu D, Chen Y, et al. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. Cell Death Dis. 2018;9(5):501. .
   PubMedGoogle Scholar
• Somasekharan SP, Elnaggar A, Leprivier G, et al. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. J Cell Biol. 2015;208(7):913–929. .
   PubMed Web of Science ®Google Scholar
• Min L, Shen YR, Jia Z, et al. Overexpression of G3BP1 correlates with poor prognosis in gastric cancer patients. Histopathology. 2015;67(5):677–688. .
   PubMed Web of Science ®Google Scholar